

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability under the Companies Ordinance)*

**(Stock Code: 00656)**

### **ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE YEAR ENDED 31 DECEMBER 2011**

On 23 March 2012, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of Fosun International Limited (the "**Company**") and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196), issued an announcement in relation to the extract of the annual report for the year ended 31 December 2011 (the "**Announcement**").

The board of directors of the Company would like to draw the attention of its shareholders and the investment public to the following principal financial data and indicators of Fosun Pharma for the year ended 31 December 2011 as set out in the Announcement:

#### **Principal Financial Data**

Unit: Yuan Currency: RMB

	2011	2010	Increase/decrease of this year as compared with last year (%)	2009
Total operation revenue	6,485,540,800.81	4,555,421,686.79	42.37	3,872,256,326.96
Operating profit	1,580,506,130.01	1,140,454,079.09	38.59	3,212,031,695.64
Profit before tax	1,726,661,261.42	1,201,951,313.26	43.65	3,264,668,429.22
Net profit attributable to shareholders of the listed company	1,165,607,629.27	863,653,906.80	34.96	2,498,201,836.08

Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	565,240,739.21	374,374,117.10	50.98	374,112,529.25
Net cash flow from operating activities	316,649,971.37	203,362,919.33	56	261,867,525.18
	End of 2011	End of 2010	Increase/decrease as at the end of this year as compared with the end of last year (%)	End of 2009
Total assets	22,290,818,173.51	16,832,939,898.40	32.42	11,527,145,937.29
Total liabilities	10,919,990,625.00	7,421,055,968.81	47.15	4,575,116,173.68
Owners' equity attributable to shareholders of the listed company	9,771,863,023.84	8,423,022,972.81	16.01	6,476,522,231.34
Total share capital	1,904,392,364.00	1,904,392,364.00	Not applicable	1,237,774,909.00

### Principal Financial Indicators

	2011	2010	Increase/decrease of this year as compared with last year (%)	2009
Basic earnings per share (yuan/share)	0.61	0.46	32.61	1.35
Diluted earnings per share (yuan/share)	0.61	0.46	32.61	1.35
Earnings per share calculated under the latest share capital (yuan/share)	0.61	0.46	32.61	1.35
Basic earnings per share net of non-recurring gain or loss (yuan/share)	0.3	0.2	50	0.2
Weighted average return on equity (%)	13.04	11.5	Increased by 1.54 percentage points	47.93
Weighted average return on equity net of non-recurring gain or loss (%)	6.32	4.99	Increased by 1.33 percentage points	7.18

Net cash flow per share from operating activities (yuan/share)	0.17	0.11	54.55	0.21
	End of 2011	End of 2010	Increase/decrease as at the end of this year as compared with the end of last year (%)	End of 2009
Equity per share attributable to shareholders of the listed company (yuan/share)	5.13	4.42	16.06	5.23
Debt-asset ratio (%)	48.99	44.09	Increased by 4.9 percentage points	39.69

Note: The full text of the annual report for the year ended 31 December 2011 of Fosun Pharma and the Announcement will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

Shanghai, the PRC, 23 March 2012

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetang and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.*